Skip to Content

GlaxoSmithKline PLC ADR GSK

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Undervalued Glaxo Posts Soft Q1, Hurt by COVID-19 Headwinds, but Long-Term Projections Look Steady

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

GlaxoSmithKline reported soft first-quarter results that were largely affected by heavy stocking in the prior-year quarter caused by the pandemic. We're not making any major changes to our fair value estimate and continue to view the stock as undervalued, with the market more focused on the likely upcoming dividend cut instead of the firm’s long-term growth potential.

Read Full Analysis

Company Profile

Business Description

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

Contact
980 Great West Road
Brentford, Middlesex, TW8 9GS, United Kingdom
T +44 2080475000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 94,066

Related